Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.
CLINICAL IMPACT OF EARLY MOLECULAR RESPONSE IN CML PATIENTS TREATED WITH IMATINIB
Vol 32, Issue 4S1, 2018
Abstract
The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first line treatment ofChronic Myeloid Leukemia (CML) has generated a need for early molecular parameters predictive ofinadequate responses to the first-generation TKI imatinib mesylate (IM). Several groups have shown thatBCR-ABL/ABLIS transcript levels <10% after 3 months (mos) or <1% after 6 mos of IM are stronglyassociated with superior clinical outcomes. We wanted to investigate which BCR-ABL threshold wouldbe more reliable in predicting treatment outcome in patients (pts) with discordant molecular transcriptsat the 3 and 6 mos time points, and also wished to evaluate if early molecular responses predicted theprobability of achieving a sustained deep molecular response.
References
Supporting Agencies
Copyright (c) 2018
This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Medical Genetics, University of Torino Medical School, Italy
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy